Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776666 | 0.89 | NR4A2 (0.48) | NR4A2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL4238309 | 0.86 | NR4A2 (0.60) | NR4A2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL4238826 | 0.85 | MGAM (0.48) | NR4A2KDM4E | |
| SCHEMBL27529206 | 0.83 | NR4A2 (0.43) | NR4A2 | |
| Hydrochloric Acid SCHEMBL4239919 | 0.83 | AKR1C3 (0.42) | NR4A2ALDH1A1 | |
| SCHEMBL4244200 | 0.80 | NR4A2 (0.39) | NR4A2ALDH1A1THRBSMN1; SMN2 | |
| SCHEMBL13855106 | 0.80 | SLC9A1 (0.43) | NR4A2 | |
| Hydrochloric Acid SCHEMBL4240463 | 0.79 | HDAC1 (0.38) | NR4A2ALDH1A1THRBSMN1; SMN2 | |
| SCHEMBL4240311 | 0.79 | NR4A2 (0.59) | NR4A2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL408819 | 0.78 | NR4A2 (1.00) | NR4A2MAPTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | IDO1, IDO2, HTR3C | NR4A2 2855/4885MAPT 1403/4885KMT2A 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.